These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25581050)

  • 41. Persistent megalocystic ovary following in vitro fertilization in a postpartum patient with polycystic ovarian syndrome.
    Ling SY; Chong KM; Hwang JL
    Taiwan J Obstet Gynecol; 2006 Mar; 45(1):70-2. PubMed ID: 17272214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of ovarian hyperstimulation syndrome guidelines. Produced on behalf of the BFS Policy and Practice Committee.
    Tan BK; Mathur R;
    Hum Fertil (Camb); 2013 Sep; 16(3):160-1. PubMed ID: 23705631
    [No Abstract]   [Full Text] [Related]  

  • 43. Natural ovarian stimulation (NATOS): effectively natural.
    Fanchin R
    Fertil Steril; 2017 May; 107(5):1120-1121. PubMed ID: 28390690
    [No Abstract]   [Full Text] [Related]  

  • 44. Adverse effects of excessive ovarian response on the pregnancy rate of in vitro fertilization treatment.
    Ng EH
    Gynecol Endocrinol; 2009 Jan; 25(1):2-7. PubMed ID: 19165656
    [No Abstract]   [Full Text] [Related]  

  • 45. Defining case-control studies.
    Ntui A; Shendre A; Lee L; McGwin G
    Fertil Steril; 2011 Jun; 95(8):e59; author reply e60. PubMed ID: 21536275
    [No Abstract]   [Full Text] [Related]  

  • 46. Minimal stimulation IVF vs conventional IVF: a randomized controlled trial.
    Zhang JJ; Merhi Z; Yang M; Bodri D; Chavez-Badiola A; Repping S; van Wely M
    Am J Obstet Gynecol; 2016 Jan; 214(1):96.e1-8. PubMed ID: 26259908
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IVF, IVM, natural cycle IVF, minimal stimulation IVF - time for a rethink.
    Edwards RG
    Reprod Biomed Online; 2007 Jul; 15(1):106-19. PubMed ID: 17623547
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports.
    Martínez F; Rodríguez DB; Buxaderas R; Tur R; Mancini F; Coroleu B
    Fertil Steril; 2011 Jun; 95(7):2432.e17-9. PubMed ID: 21513932
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of thromboembolism in relation to an in-vitro fertilization programme: three case reports.
    Aurousseau MH; Samama MM; Belhassen A; Herve F; Hugues JN
    Hum Reprod; 1995 Jan; 10(1):94-7. PubMed ID: 7745079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rescue hCG to treat empty follicle syndrome after the use of a GnRH agonist as oocyte maturation trigger: First report on fresh embryo transfer and clinical pregnancy.
    Christopoulos G; Vlismas A; Barsoum-Derias E; El-Shawarby S; Trew G; Lavery S
    Hum Fertil (Camb); 2015; 18(4):248-52. PubMed ID: 26400626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidemiology of multiple pregnancy and the effect of assisted conception.
    Black M; Bhattacharya S
    Semin Fetal Neonatal Med; 2010 Dec; 15(6):306-12. PubMed ID: 20630816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The need for new methods of ovarian stimulation.
    Crosignani PG
    Reprod Biomed Online; 2002; 5 Suppl 1():57-60. PubMed ID: 12537783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome.
    Spitzer D; Wogatzky J; Murtinger M; Zech MH; Haidbauer R; Zech NH
    Fertil Steril; 2011 Jun; 95(8):2742-4.e1. PubMed ID: 21411081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection.
    Polyzos NP; Tournaye H; Guzman L; Camus M; Nelson SM
    Fertil Steril; 2013 Aug; 100(2):430-7. PubMed ID: 23668992
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Groningen ART cohort study: ovarian hyperstimulation and the in vitro procedure do not affect neurological outcome in infancy.
    Middelburg KJ; Heineman MJ; Bos AF; Pereboom M; Fidler V; Hadders-Algra M
    Hum Reprod; 2009 Dec; 24(12):3119-26. PubMed ID: 19749193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee.
    Tan BK; Mathur R
    Hum Fertil (Camb); 2013 Sep; 16(3):151-9. PubMed ID: 23705784
    [No Abstract]   [Full Text] [Related]  

  • 58. Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes.
    Styer AK; Gaskins AJ; Brady PC; Sluss PM; Chavarro JE; Hauser RB; Toth TL
    Fertil Steril; 2015 Nov; 104(5):1153-61.e1-7. PubMed ID: 26315051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Study on clinical effect on infertility women with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer].
    Yu R; Lin J; Zhao JZ; Wang PY; Xiao SQ; Zhang W
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):250-4. PubMed ID: 22781109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?
    Fauser BC; Devroey P
    Fertil Steril; 2005 Jun; 83(6):1607-11. PubMed ID: 15950626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.